WO2019205403A1 - Produit de cellules tueuses naturelles génétiquement modifiées pour le traitement d'une tumeur - Google Patents

Produit de cellules tueuses naturelles génétiquement modifiées pour le traitement d'une tumeur Download PDF

Info

Publication number
WO2019205403A1
WO2019205403A1 PCT/CN2018/103655 CN2018103655W WO2019205403A1 WO 2019205403 A1 WO2019205403 A1 WO 2019205403A1 CN 2018103655 W CN2018103655 W CN 2018103655W WO 2019205403 A1 WO2019205403 A1 WO 2019205403A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
natural killer
genetically engineered
cell
gene
Prior art date
Application number
PCT/CN2018/103655
Other languages
English (en)
Chinese (zh)
Inventor
张书元
徐卫
Original Assignee
赛诺（深圳）生物医药研究有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 赛诺（深圳）生物医药研究有限公司 filed Critical 赛诺（深圳）生物医药研究有限公司
Publication of WO2019205403A1 publication Critical patent/WO2019205403A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

L'invention concerne un produit de cellules tueuses naturelles génétiquement modifiées pour le traitement de tumeurs. Ledit produit cellulaire est obtenu par transfert stable de gènes IL-2 et HSV-tk humains dans des cellules tueuses naturelles (NK) au moyen d'un procédé d'ingénierie génétique.
PCT/CN2018/103655 2018-04-27 2018-08-31 Produit de cellules tueuses naturelles génétiquement modifiées pour le traitement d'une tumeur WO2019205403A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810392435.3A CN108531458A (zh) 2018-04-27 2018-04-27 治疗肿瘤的基因工程自然杀伤细胞产品
CN201810392435.3 2018-04-27

Publications (1)

Publication Number Publication Date
WO2019205403A1 true WO2019205403A1 (fr) 2019-10-31

Family

ID=63477705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/103655 WO2019205403A1 (fr) 2018-04-27 2018-08-31 Produit de cellules tueuses naturelles génétiquement modifiées pour le traitement d'une tumeur

Country Status (2)

Country Link
CN (1) CN108531458A (fr)
WO (1) WO2019205403A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202115245A (zh) * 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1493687A (zh) * 2003-09-05 2004-05-05 中国科学技术大学 白细胞介素-15基因修饰的自然杀伤细胞株及其制备方法
CN105950630A (zh) * 2012-02-01 2016-09-21 浦项工科大学校产学协力团 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10209451A1 (de) * 2002-03-05 2003-09-18 Universitaetsklinikum Hamburg Spezifische Genexpression in Kolonkarzinom-Zell-Linien
WO2013040371A2 (fr) * 2011-09-16 2013-03-21 Baylor College Of Medicine Ciblage du microenvironnement tumoral au moyen de cellules nkt modifiées
CN107427578A (zh) * 2015-03-27 2017-12-01 南克维斯特公司 用于治疗癌症的被遗传修饰的nk‑92细胞和单克隆抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1493687A (zh) * 2003-09-05 2004-05-05 中国科学技术大学 白细胞介素-15基因修饰的自然杀伤细胞株及其制备方法
CN105950630A (zh) * 2012-02-01 2016-09-21 浦项工科大学校产学协力团 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI CHUNHUI: "Experiment of Glioma Treated with Bone Marrow Stromal Cells Co-Transfected with HSV-tk, IL -18", CHINA DOCTORAL DISSERTATION, 31 December 2007 (2007-12-31) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity

Also Published As

Publication number Publication date
CN108531458A (zh) 2018-09-14

Similar Documents

Publication Publication Date Title
EP3258943B1 (fr) Association d'une immunothérapie et d'une thérapie de contrôle des cytokines pour le traitement du cancer
JP2021169473A (ja) 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株
Oberschmidt et al. Development of automated separation, expansion, and quality control protocols for clinical-scale manufacturing of primary human NK cells and alpharetroviral chimeric antigen receptor engineering
TW202035685A (zh) 組合癌症免疫療法
KR101909879B1 (ko) 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물
Jamali et al. Highly efficient generation of transgenically augmented CAR NK cells overexpressing CXCR4
JP6971986B2 (ja) 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
Minagawa et al. Generation of suicide gene-modified chimeric antigen receptor-redirected T-cells for cancer immunotherapy
JP6073417B2 (ja) 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
KR20200001595A (ko) 형질전환된 t세포를 이용한 자연살해세포의 배양방법
WO2019205403A1 (fr) Produit de cellules tueuses naturelles génétiquement modifiées pour le traitement d'une tumeur
KR20210013013A (ko) 종양 치료 방법 및 조성물
US20220064599A1 (en) Car nk cells
WO2020167648A1 (fr) Génération de lymphocytes t régulateurs de type 1 par ciblage des facteurs de transcription
JP7179986B2 (ja) 形質転換されたｔ細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法
Jiang et al. Human induced-T-to-natural killer cells have potent anti-tumour activities
Karvouni et al. Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide
WO2022216831A1 (fr) Traitement du cancer par des cellules nk et un anticorps ciblant l'her2
EP4319772A1 (fr) Traitement du cancer avec des cellules nk et un anticorps ciblant l'egfr
EP4319769A1 (fr) Traitement du cancer par des cellules nk et un anticorps ciblant le cd20
JP2023504075A (ja) Ｃａｒ－ｎｋ細胞を得る方法
KR20220078665A (ko) 다중특이적 면역 세포 인게이저를 발현하는 종양용해 바이러스
US20190321402A1 (en) Nk cells for use with anitbodies in cancer therapy
Chu et al. Coupling programmed cell death 1-positive tumor-infiltrating t cells with anti-programmed cell death 1 antibody improves the efficacy of adoptive T-cell therapy
Nakazawa et al. An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18916288

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 21/12/2020)

122 Ep: pct application non-entry in european phase

Ref document number: 18916288

Country of ref document: EP

Kind code of ref document: A1